103 related articles for article (PubMed ID: 22252391)
1. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.
Jugdutt BI
Clin Interv Aging; 2010 Dec; 5():403-16. PubMed ID: 21152242
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan ameliorates nephropathy and restores the hippo pathway in rats with metabolic syndrome.
Mohamed B; Ghareib SA; Alsemeh AE; El-Sayed SS
Eur J Pharmacol; 2024 Jun; 973():176605. PubMed ID: 38653362
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice.
Krieger MH; Di Lorenzo A; Teutsch C; Kauser K; Sessa WC
Lab Invest; 2010 Nov; 90(11):1573-81. PubMed ID: 20585312
[TBL] [Abstract][Full Text] [Related]
5. HIV-associated nephropathy: role of AT2R.
Salhan D; Sagar A; Kumar D; Rattanavich R; Rai P; Maheshwari S; Adabala M; Husain M; Ding G; Malhotra A; Chander PN; Singhal PC
Cell Signal; 2012 Mar; 24(3):734-41. PubMed ID: 22108089
[TBL] [Abstract][Full Text] [Related]
6. Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity.
Ayza MA; Zewdie KA; Tesfaye BA; Gebrekirstos ST; Berhe DF
Diabetes Metab Syndr Obes; 2020; 13():3627-3635. PubMed ID: 33116714
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.
Vitale C; Mercuro G; Castiglioni C; Cornoldi A; Tulli A; Fini M; Volterrani M; Rosano GM
Cardiovasc Diabetol; 2005 May; 4():6. PubMed ID: 15892894
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease.
Kohan DE; Bedard PW; Jenkinson C; Hendry B; Komers R
Clin Sci (Lond); 2024 Jun; 138(11):645-662. PubMed ID: 38808486
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension.
Kara SC; Canpolat U
Turk Kardiyol Dern Ars; 2024 Apr; 52(3):217-219. PubMed ID: 38573089
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients.
Takagi H; Umemoto T;
J Am Soc Hypertens; 2014 Aug; 8(8):578-92. PubMed ID: 25151319
[TBL] [Abstract][Full Text] [Related]
11. Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis.
Foulquier S; Böhm M; Schmieder R; Sleight P; Teo K; Yusuf S; Schumacher H; Unger T
J Hypertens; 2014 Jun; 32(6):1334-41. PubMed ID: 24621807
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: "TRIUMF trial".
Samir A; Aboel-Naga S; Shehata A; Abdelhamid M
Egypt Heart J; 2023 Aug; 75(1):68. PubMed ID: 37552407
[TBL] [Abstract][Full Text] [Related]
13. Anti-Apoptosis of Podocytes and Pro-Apoptosis of Mesangial Cells for Telmisartan in Alleviating Diabetic Kidney Injury.
Wei X; Ma Y; Li Y; Zhang W; Zhong Y; Yu Y; Zhang LC; Wang Z; Tu Y
Front Pharmacol; 2022; 13():876469. PubMed ID: 35517816
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Angiogenesis Using HGF Plasmid.
Sanada F; Fujikawa T; Shibata K; Taniyama Y; Rakugi H; Morishita R
Ann Vasc Dis; 2020 Jun; 13(2):109-115. PubMed ID: 32595785
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome Proliferator-Activated Receptor gamma negatively regulates liver regeneration after partial hepatectomy via the HGF/c-Met/ERK1/2 pathways.
Cheng Z; Liu L; Zhang XJ; Lu M; Wang Y; Assfalg V; Laschinger M; von Figura G; Sunami Y; Michalski CW; Kleeff J; Friess H; Hartmann D; Hüser N
Sci Rep; 2018 Aug; 8(1):11894. PubMed ID: 30089804
[TBL] [Abstract][Full Text] [Related]
16. Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies.
Lv W; Booz GW; Fan F; Wang Y; Roman RJ
Front Physiol; 2018; 9():105. PubMed ID: 29503620
[TBL] [Abstract][Full Text] [Related]
17. Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets.
Lv W; Booz GW; Wang Y; Fan F; Roman RJ
Eur J Pharmacol; 2018 Feb; 820():65-76. PubMed ID: 29229532
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte Growth Factor Prevented High-Fat Diet-Induced Obesity and Improved Insulin Resistance in Mice.
Muratsu J; Iwabayashi M; Sanada F; Taniyama Y; Otsu R; Rakugi H; Morishita R
Sci Rep; 2017 Mar; 7(1):130. PubMed ID: 28273932
[TBL] [Abstract][Full Text] [Related]
19. Alternative Interventions to Prevent Oxidative Damage following Ischemia/Reperfusion.
Rodríguez-Lara SQ; Cardona-Muñoz EG; Ramírez-Lizardo EJ; Totsuka-Sutto SE; Castillo-Romero A; García-Cobián TA; García-Benavides L
Oxid Med Cell Longev; 2016; 2016():7190943. PubMed ID: 28116037
[TBL] [Abstract][Full Text] [Related]
20. Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-γ in colon.
Xia Y; Xia YF; Lv Q; Yue MF; Qiao SM; Yang Y; Wei ZF; Dai Y
Br J Pharmacol; 2016 Apr; 173(7):1219-35. PubMed ID: 26750154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
